Keyword Analysis & Research: lutonix dcb


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
lutonix dcb1.510.947748911
lutonix0.370.99174657
dcb0.730.467391003

Keyword Research: People who searched lutonix dcb also searched

Keyword CPC PCC Volume Score
lutonix dcb0.530.141137
lutonix av dcb1.50.4334269

Search Results related to lutonix dcb on Search Engine

  • Lutonix™ Drug Coated Balloon PTA Catheters | BD

    bd.com

    https://www.bd.com/en-us/products-and-solutions/products/product-families/lutonix-drug-coated-balloon-pta-catheters

    WEBThe Lutonix™ DCB delivers a dose of 2 µg/mm 2 of paclitaxel and is designed to provide the versatility needed to treat lesions of varying sizes and lengths. It is engineered to enhance femoropopliteal procedures by providing: A robust size matrix. Extensive indications. Proven results in a Level 1 Clinical Trial 1. 1. 2. 3. 4. 5. 6. 7. 8.

    DA: 47 PA: 85 MOZ Rank: 60

  • Lutonix™ 035 DCB – Dysfunctional AV Fistula Indication | BD

    bd.com

    https://www.bd.com/en-us/products-and-solutions/products/product-families/lutonix-035-dcb-dysfunctional-av-fistula-indication

    WEBIndication for Use. The Lutonix™ Catheter is indicated for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for treatment of stenotic lesions of dysfunctional native arteriovenous dialysis fistulae that are 4 mm to …

    DA: 47 PA: 72 MOZ Rank: 24

  • Lutonix™ Drug Coated Balloon PTA Catheters - BD

    bd.com

    https://www.bd.com/en-uk/products-and-solutions/products/product-families/lutonix-drug-coated-balloon-pta-catheters

    WEBThe Lutonix™ DCB delivers a dose of 2 µg/mm 2 of paclitaxel and is designed to provide the versatility needed to treat lesions of varying sizes and lengths. It is engineered to enhance femoropopliteal procedures by providing: A robust size matrix. Extensive indications. Proven results in a Level 1 Clinical Trial 1. 1. 2. 3. 4. 5. 6. 7. 8.

    DA: 20 PA: 54 MOZ Rank: 24

  • LUTONIX® 035 Drug Coated Balloon PTA Catheter

    fda.gov

    https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130024d.pdf

    WEBThe Lutonix 035 Drug Coated Balloon PTA catheter is indicated for percutaneous transluminal angioplasty, after pre-dilatation, of de novo or restenotic lesions up to 150mm in length in native...

    DA: 33 PA: 82 MOZ Rank: 2

  • Randomized Trial of Chocolate Touch Compared With Lutonix …

    ahajournals.org

    https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059646

    WEBApr 4, 2022 · In this prospective, multicenter, randomized trial, the second-generation Chocolate Touch DCB met both noninferiority end points for efficacy and safety and was more effective than Lutonix DCB at 12 months for the treatment of femoropopliteal disease. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02924857.

    DA: 73 PA: 13 MOZ Rank: 84

  • LutonixTM 014 Drug Coated Balloon PTA Catheter for …

    fda.gov

    https://www.fda.gov/media/146132/download

    WEBLutonix DCB: Safe Treatment Option for Patients with Critical Limb Ischemia (CLI) Debilitating, ultimately life-threatening disease Limited treatment options require frequent, early...

    DA: 57 PA: 48 MOZ Rank: 21

  • BD Newsroom - Press releases

    bd.com

    https://news.bd.com/2023-11-01-BD-Registry-Underscores-Value-of-the-Lutonix-TM-Drug-Coated-Balloon-DCB-Technology-in-Treating-Femoropopliteal-Disease

    WEBNov 1, 2023 · BD Registry Underscores Value of the Lutonix™ Drug Coated Balloon (DCB) Technology in Treating Femoropopliteal Disease. Results of the SAFE-DCB Registry support long-term safety and effectiveness for the Lutonix™ DCB in a real-world patient population with femoropopliteal disease.

    DA: 43 PA: 37 MOZ Rank: 53

  • Leading with - BD

    bd.com

    https://lp.bd.com/rs/328-BFZ-688/images/BD-46490_Lutonix_family_brochure.pdf

    WEBThe LutonixTM 014 product line features: All 4F sheath compatibility. Dual distal marker bands. GeoAlignTM Marking System. 6 month safety* DCB. 97.8% PTA 95.3% 6 month efficacy* DCB. 73.7. MORE DAYS BEFORE FIRST TLR. *As of July 2019 in the U.S. Percentages reported are derived from Kaplan-Meier analyses at 180 days.

    DA: 36 PA: 35 MOZ Rank: 13

  • The Lutonix® drug-coated balloon: A novel drug delivery technology for

    sciencedirect.com

    https://www.sciencedirect.com/science/article/pii/S0169409X17300716

    WEBMar 1, 2017 · This review article summarizes the development of the LUTONIX® drug coated balloon catheter. The introduction of DCB technology has provided clinicians and patients with new SFA treatment options while ongoing clinical evidence in additional vascular beds is generated.

    DA: 84 PA: 52 MOZ Rank: 19

  • Premarket Approval Application (PMA) for the Lutonix 014 …

    fda.gov

    https://www.fda.gov/media/146130/download

    WEBPremarket Approval Application (PMA) for the Lutonix 014 Drug Coated Balloon (Lutonix 014 DCB) . Cardiovascular Devices Advisory Panel Meeting February 17, 2021 .

    DA: 21 PA: 25 MOZ Rank: 52


© 2021. All rights reserved